Retroscreen Virology Group, which creates drugs and vaccines for a number of viral respiratory diseases, has signed a Viral Challenge Model contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study.
The contract, valued at £5.9m, will be the largest RSV challenge study conducted by Retroscreen to-date.
Kym Denny, Chief Executive Officer, said: "We are delighted to be working with such an innovative pharmaceutical company on the development of their novel product.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This contract win comes from the building momentum of Retroscreen's sales pipeline and highlights the pharmaceutical industry's increasing awareness of the benefits of the VCM in accelerating drug development and product decision-making."
NR
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the USMedium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.
